BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Compliant with Nasdaq Bid Price Rule

Jaguar Health (JAGX)Jaguar HealthCompany update

JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that

Related news

JAGXJaguar Health2026-05-08 13:00 EST

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

JAGXJaguar Health2026-04-27 13:00 EST

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

ALZNAlzamend Neuro2026-08-04 12:00 EST

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

SCYXSCYNEXIS2026-08-25 23:06 EST

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2025-12-22 13:00 EST

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

IBRXImmunityBio2026-08-10 13:00 EST

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

IBRXImmunityBio2026-05-07 11:30 EST

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-09-15 13:00 EST

Jaguar Health, Inc. Announces Reverse Stock Split

JAGXJaguar Health2026-09-10 13:00 EST

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

JAGXJaguar Health2026-09-08 13:00 EST

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

JAGXJaguar Health2026-09-04 12:30 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

JAGXJaguar Health2026-08-26 13:00 EST

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Stock data

Close
2.75 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California